Vista Pharmaceuticals: Zero Revenue, Growing Losses, and Going Concern Risk in Q1FY27
Vista Pharmaceuticals Ltd · Outcome · 14 Aug 2026, 9:06 pm
Vista Pharmaceuticals: Zero Revenue, Growing Losses, and Going Concern Risk in Q1FY27 Vista Pharmaceuticals reported zero revenue from operations for Q1FY27 ended 30 Jun'26, down from ₹151.88 lakhs YoY. The net loss narrowed slightly to ₹98.59 lakhs from ₹129.04 lakhs YoY, while the loss before tax was ₹132.71 lakhs. Significant financial stress is evident, with credit facilities classified as NPAs, negative working capital, and current liabilities exceeding current assets by ₹183.32 lakhs. These factors raise material uncertainty about its ability to continue as a going concern, despite management preparing results on that basis.
Original exchange filing (PDF)
More announcements from Vista Pharmaceuticals Ltd
- Resignation of Company Secretary & Compliance Officer · 12 Sept 2026
- Results for the quarter ended 30.06.2026 · 14 Aug 2026
- Vista Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve 1. Unaudited financial .... · 14 Aug 2026
- Board meeting outcome · 29 May 2026
- Vista Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve 1. Audited financial .... · 29 May 2026
- <b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> .... · 29 Apr 2026
- Un audited Financial Results for the quarter ended 31.12.2025 · 13 Feb 2026
- Results for the quarter ended 31.12.2025 · 13 Feb 2026
